TVA

TVA

TVA

Product catalog summary
Assay Principle
The Target cell Visualization Assay (TVA™) employs direct imaging of fluorescence-labeled target cells. These labeled tumor cells are co-incubated with Peripheral Blood Mononuclear Cells (PBMC) or other NK cell-containing isolates. NK-mediated lysis results in the loss of fluorescent signal from target cells. The assay determines cytotoxicity by visualizing remaining viable target cells, allowing for the assessment of different effector to target (E:T) ratios. Up to three differently labeled target cells can be tested simultaneously.
Assay Sensitivity
The TVA™ and the Chromium Release Assay (CRA) show similar killing percentages, regardless of whether cryopreserved or freshly-isolated PBMCs are used. Both assays are sensitive in a 96-well plate format, but TVA™ is less labor-intensive and requires less time. It offers no background noise, high reproducibility, and audit trails. TVA™ matches CRA in sensitivity and can measure lysis of up to three different target cells simultaneously, reducing the number of effector cells needed by 30-fold.
Assay Miniaturization
Traditional cytotoxicity assays require large numbers of effector cells. The TVA™ can be miniaturized, needing only 1x105 PBMCs for assessing seven E:T ratios in Terasaki plates run in triplicate. The lytic activity measured is similar to that in 96-well plate formats.
Comparison: TVA™ vs. CRA
  • Non-radioactive: TVA™ ✔, CRA ✖
  • Direct visualization: TVA™ ✔, CRA ✖
  • Number of cells required: TVA™ 1x106 (96-well), 1x105 (Terasaki); CRA 2x106
  • Background noise: TVA™ ✖, CRA ✔
  • Labor intensive: TVA™ ✖, CRA ✔
  • Automated analysis: TVA™ ✔, CRA ✖
  • Audit trails: TVA™ ✔, CRA ✖
  • Assay kit and consultation available: TVA™ ✔, CRA ✖
Conclusion
The TVA™ offers a faster, simpler, and more precise method for detecting NK-mediated cell cytotoxicity, requiring fewer effector cells. It is a non-radioactive alternative to CRA, providing direct visualization and automated analysis, making it suitable for laboratories operating under GLP.
See more

Catalog excerpts

TVA-1

Non-Radioactive NK/ADCC Activity Assessment or decades, the Chromium Release Assay (CRA) has been the gold standard for measuring Natural Killer (NK) cell-mediated lysis of tumor cells, or of antibody coated target cells (ADCC). Until now, CRA has been unparalleled in sensitivity. No longer! CTL’s non-radioactive Target cell Visualization Assay (TVA™) not only has the same sensitivity as CRA, but can also measure the lysis of up to three different target cells simultaneously, and be performed in Terasaki plate format, thereby reducing the number of effector cells needed by 30-fold. The TVA™ Platform is based on direct, single-cell imaging, is less laborious than the CRA, and has fully-automated analysis and data reporting. Streamlined quality control and tamper-proof audit trails facilitate the work flow in laboratories that work under GLP. Assay Principle Assay Sensitivity The TVA utilizes direct imaging of fluorescence-labeled target cells. Labeled tumor cells are co-incubated at various ratios with Peripheral Blood Mononuclear Cell (PBMC) populations, or other NK cell-containing isolates. Following NK-mediated lysis, target cells lose their fluorescent signal. The direct visualization of remaining viable target cells at the end of the assay determines the percentage of cytotoxicity for each effector to target (E:T) ratio. Up to three differently labeled target cells can be tested simulataneously. When performed in parallel, the TVA™ and CRA exhibited similar killing percentages irrespective of whether cryo reserved PBMC or p freshly-isolated PBMC were used as effectors with labeled K562 as target cells. Both assays were equally sensitive in a 96-well plate assay, however, the TVA™ Platform is far less labor-intensive and requires a fraction of the investigator’s time. The TVA™ has no background noise, has high inter-assay reproducibility, and provides audit trails. CRYOPRESERVED PBMC TVA™ Chromium Release FRESH-ISOLATED PBMC Representative images from the TVA™ are shown (A). Comparison to CRA using cryopreserved (B) and freshly-isolated (C) PBMC exhibit equiva

 Open the catalog to page 1
TVA-2

Assay Miniaturization A major drawback of traditional cytotoxicity assays is that they require large numbers of effector cells to detect cytotoxic effects. The TVA™ can be performed in a miniaturized format, requiring only 1x105 PBMC for assessment of seven E:T ratios in Terasaki plates run in triplicate. The measured percentage of lytic activity is similar to that observed with 96-well plate formats. Detection of Natural Killer-mediated Cell Cytotoxicity does not have to be complicated. Join the community of researchers using the TVA™. Contact us today for a demo! ASSAY MINIATURIZATION Terasaki...

 Open the catalog to page 2
*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.